Despite Calls for a Moratorium, More ‘Three-Parent’ Babies Expected Soon
By Emily Mullin,
One Zero
| 09. 16. 2019
Clinics in Europe say they will continue offering a controversial IVF procedure
At least 10 babies have been born to apparently infertile women as a result of a controversial in vitro fertilization procedure that involves combining a mother’s egg with a donor one. The technique is often referred to as “three-person IVF” because the baby ends up with DNA from three people — the mother, the father, and an egg donor.
One of the births was reported in April by a Greek clinic performing the procedure, also known as mitochondrial replacement therapy, or mitochondrial donation. Now, fertility experts in Europe are calling for a moratorium on using the technique for women who have struggled to conceive.
The European Society of Human Reproduction and Embryology (ESHRE) has issued a statement urging “extreme caution” on the use of mitochondrial replacement for cases of infertility. The organization, which represents 8,000 clinicians and scientists, says there’s not enough evidence to show that it produces higher live-birth rates than conventional IVF. However, OneZero has learned that despite the group’s recommendation, the Greek clinic, as well as another center in Ukraine, will continue to offer the procedure —...
Related Articles
By Hannah Devlin, The Guardian | 05.14.2024
Photo by Kind and Curious from Unsplash
When Great Ormond Street hospital (Gosh) published the results of its gene therapy trial for “bubble baby” syndrome it was hailed as a medical breakthrough. The treatment had a more than 95% success...
By Victoria Bisset and Adela Suliman, The Washington Post | 05.09.2024
Photo by CDC from Unsplash
A baby girl born with profound genetic deafness can now hear unaided after receiving a “groundbreaking” gene therapy trial, Britain’s National Health Service said Thursday.
Opal Sandy, an 18-month-old from Oxfordshire, England, is the first...
By Carrie Arnold, Nature Biotechnology | 04.17.2024
Tome Biosciences came out of stealth mode on 12 December with a haul of over $200 million to develop the company’s gene editing platform. Tome’s first order of business was to snap up Replace Therapeutics to expand its toolkit to...
By Rob Stein, NPR | 04.24.2024
Lisa Pisano was lying in a hospital bed at NYU Langone Health, hooked up to beeping monitors and an array of tubes. Her surgical wounds were still healing, and she looked tired. But the 54-year-old New Jersey woman said she...